In a recent study, retrospectively analyzing samples pairwise collected from AML patients at the time of diagnosis and at post-transplantation relapse, we showed increased expression of the inhibitory molecules PD-L1, CD276/B7-H3, and CD155/PVRL2 in up to 40% of cases of relapse. The gene discussed is CD276; the disease is acute myeloid leukemia.